Qingdao Sino-cell Biomedicine Co., Ltd.
Clinical trials sponsored by Qingdao Sino-cell Biomedicine Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a Patient's own immune cells beat advanced kidney cancer? Results expected Oct 2026 (estimated)
-
A Patient's own immune cells, grown in the lab, tested against advanced lung cancer
Cure Not yet recruitingResearchers are testing an experimental cell therapy called HS-IT101 in people with advanced non-small cell lung cancer. The treatment uses tumor-infiltrating lymphocytes (TILs), immune cells taken from the patient's own tumor, multiplied in the lab, and given back. Before receiv…
Phase 1 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Cure
Last updated Sep 21, 2026 21:00 UTC
-
Can a Patient's own immune cells beat advanced kidney cancer?
Cure Not yet recruitingThis early-stage trial is testing an experimental therapy called HS-IT101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. The treatment involves collecting immune cells from the patient's tumor, multiplying them in the lab, and infusing them bac…
Phase 1 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Personalized cell therapy takes on advanced melanoma in new trial
Disease control Not yet recruitingThis Phase 2 trial tests whether a personalized cell therapy called HS-IT101 works better than chemotherapy for people with advanced melanoma that has stopped responding to standard treatments. HS-IT101 uses a patient's own immune cells, grown in large numbers in a lab, to fight …
Phase 2 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC